Astrazeneca CEO Pascal Sorrio claims that the UK is better than Europe in terms of Covid-19, as the Oxford / Astrazeneca vaccine is more widely used in the elderly population in the UK.
According to News, several European countries are re-applying quarantine and Covid-19 restrictions as the number of infections has increased in recent weeks. “While Britain has more infections than the rest of Europe, relatively few people are hospitalized,” Sorio said.
He claimed that the reason for this low rate was the injection of the Oxford / Astrazeneca vaccine, which was used for the elderly population in Britain.
Sorio argues that the vaccine stimulates higher levels of T cells in the elderly.
“Covid-19 vaccines do two things; Stimulation of antibody response and T cell response But antibodies decrease over time and T cells are more durable.
“It takes some time for T cells to respond, and during that time you may become infected, but eventually they come to your aid and you are not hospitalized,” said Astrazeneca CEO.
This is the reason for the increase in the number of infections in Europe, but in the UK, despite the large number of infections, the number of hospitalizations is lower than in Europe.
In the UK, the vaccine is used to vaccinate the elderly, while in Europe it is thought to be ineffective in the elderly.
‘Rough’ recommendation of vaccination to German citizens coincides with the fourth wave of the corona
Danny Altman, professor of immunology at Imperial College London, said: “There are subtle differences in vaccines, but the efficacy is similar, and the Oxford / Astrazeneca vaccine has been very helpful but not specific.
“Although the Astraznka vaccine may have a better T-cell response, we do not yet know for sure,” said Dr Lance Tartel, senior clinical lecturer and infectious disease consultant at the University of Liverpool.
He added: “Therefore, more studies are needed to determine the cause, and at present it is not possible to say with certainty whether the Astraznka vaccine is better than any other vaccine.”
“Based on real-world experience, this is unlikely to be the case, and if it is, the difference is likely to be small,” Tartel said.
Matthew Snape, an associate professor of pediatrics and immunology at Oxford University, said: “Studies have shown that a single dose of the Oxford / Astrazenka vaccine induces a better T cell response than a Pfizer injection, but shortly after two doses, T cells in both types.” The vaccines had very similar responses.
“Different vaccines have been injected at different times and in different groups of people at risk for severe disease, so it is very difficult to compare them directly,” said Eleanor Riley, a professor of immunology and infectious diseases at the University of Edinburgh.
According to official figures, the number of weekly deaths of Covid-19 in England and Wales exceeded 1,000 for the first time in eight months, and 1,020 deaths from corona were recorded in the week ending November 12.
Sorio stressed that he does not believe countries have made a mistake in not providing vaccines to older populations, and that there is a lot of data that still needs to be available.
The Oxford / Astrazeneca vaccine was widely used at the beginning of the British vaccination campaign, when the elderly and the most vulnerable were among the first to receive the Covid vaccine, but many European countries feared the vaccine might be linked to blood clots. Its rare side effects were the decision to discontinue the Oxford / Astrazeneca vaccine.
There have already been suggestions that the expansion of booster injections in the UK could save it from the fourth wave of infections that has swept across Europe, and the government has responded to calls for a “Plan B” of Covid-19 measures in the UK during Winter has resisted and is more focused on increasing the absorption of booster injections as the best line of battle.
Most people in the UK are offered Pfizer or Modern vaccines as a booster dose.
Asked if he was disappointed that the Oxford / Astrazenka vaccine was not being used as a booster vaccine in the UK, Surio said: “Each country has its own decisions and it was easier to choose a vaccine sample to boost everyone across the country.”
Revealing a 1 billion R&D center in Cambridge, Britain’s largest science lab, he said he had no regrets about the vaccine.
It should be noted that European countries, including Germany, Hungary and Spain, are implementing a booster dose plan against Covid-19 to counteract the decline in immunity.